Workplace safety and the opioid crisis intersect in profound ways, necessitating proactive strategies to mitigate risks and support employees. The expanded opiate drug test is a comprehensive approach that goes beyond traditional screening methods. It includes a broader range of opioids, such as prescription drugs, illicit substances, and synthetics.
Click to jump to the section:
According to the National Survey on Drug Use and Health (NSDUH), an estimated 10.1 million Americans misused opioids in 2020, with approximately 8.3 million using prescription pain relievers non-medically.
Workplace drug testing has focused on the detection of standard opiates, such as morphine and codeine. However, due to the evolving landscape of opioid misuse and the emergence of various potent synthetic opioids, standard drug testing protocols may not provide a comprehensive assessment of opiate abuse. To address this gap, an expanded opiates drug test has been developed to encompass a broader range of substances.
Expanded opioid drug testing offers employers a comprehensive approach, enabling them to identify and address opioid use, implement tailored prevention initiatives, and create a drug-free workplace environment.
The drugs typically included in an expanded opiate drug panel for workplace drug testing may vary based on specific testing protocols and regulatory guidelines. However, here is a list of opioids commonly encompassed in testing for expanded opiates:
Expanded opiate drug testing represents a critical step forward in addressing the complex issue of opioid abuse in the workplace. By detecting a wider range of opiates, including potent synthetic opioids, employers can take proactive measures to safeguard their workforce and create a healthier, more productive work environment. However, implementing expanded opiate drug testing requires a thoughtful approach, combining comprehensive drug policies, supportive drug testing programs, and adherence to legal and ethical guidelines.
Employers may consult with third-party administrators to determine the appropriate substances to include in their workplace testing for expanded opioids.